EE152 Cost-Effectiveness Modeling of Lurbinectedin As a Second-Line Therapy in Patients with Small Cell Lung Cancer (SCLC)

W. Su, B. Rengarajan, D. Profant, K. Mayo, M. Groff,G. Tremblay, A.K. Ganti

Value in Health（2023）

引用 0|浏览4

暂无评分

摘要

To model the cost-effectiveness of second-line lurbinectedin treatment in adults with metastatic SCLC with disease progression on or after platinum-based chemotherapy in the US.

查看译文

关键词

lurbinectedin,cell lung cancer,small cell lung cancer,cost-effectiveness,second-line

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要